SAN DIEGO, Jul 27, 2010 (BUSINESS WIRE) --
Illumina, Inc. (NASDAQ:ILMN) today announced its financial results for the second quarter of 2010.
Second quarter 2010 results:
- Revenue of $212.0 million, a 31% increase over the $161.6 million reported in the second quarter of 2009.
- GAAP net income for the quarter of $29.8 million, or $0.21 per diluted share, compared to net income of $24.7 million, or $0.18 per diluted share, for the second quarter of 2009. Net income for the second quarter of 2010 included $5.2 million in non-cash interest expense and other items listed in the table entitled "An Itemized Reconciliation Between GAAP and Non-GAAP Net Income."
- Non-GAAP net income for the quarter of $34.0 million, or $0.26 per diluted share, compared to $29.2 million, or $0.22 per diluted share, for the second quarter of 2009.
Gross margin in the second quarter of 2010 was 68.9% compared to 68.8% in the comparable period of 2009. Excluding the effect of non-cash charges associated with stock compensation and the amortization of intangibles, non-GAAP gross margin was 70.3% for the second quarter of 2010 compared to 70.6% in the prior year period.
Research and development (R&D) expenses for the second quarter of 2010 were $43.7 million compared to $33.1 million in the second quarter of 2009. R&D expenses include $6.0 million and $5.0 million of non-cash stock compensation expense in the second quarter of 2010 and 2009, respectively. R&D expenses in both periods also include $0.9 million of accrued contingent compensation. Excluding these charges, R&D expenses as a percentage of revenue were 17.3% compared to 16.8% in the prior year period.
Selling, general, and administrative (SG&A) expenses for the second quarter of 2010 were $53.7 million compared to $41.9 million for the second quarter of 2009. SG&A expenses include $9.4 million and $8.6 million of non-cash stock compensation expense in the second quarter of 2010 and 2009, respectively. SG&A expense also includes $0.5 million of acquisition costs (see acquisition of Helixis, below) in the second quarter of 2010. Excluding these charges, SG&A expenses as a percentage of revenue were 20.6% in the second quarter of 2010 and 2009.
The company generated $74.8 million in cash flow from operations during the second quarter of 2010 compared to $39.4 million in the prior year period. Depreciation and amortization expenses were $10.2 million and capital expenditures were $13.1 million during the second quarter. The company ended the second quarter with $785.4 million in cash and investments compared to $693.5 million as of January 3, 2010.
Highlights since our last earnings release:
- Completed the acquisition of Helixis, Inc., a company developing a new generation of high-performance, low-cost, Real-Time PCR systems used for genetic analysis, for $70.0 million in cash and up to $35 million in contingent consideration. In conjunction with the close of the acquisition, Illumina appointed Helixis CEO, Alex Dickinson to Senior Vice President of PCR Solutions.
- Received authorization from the Board of Directors for a $200 million stock buyback program, with $100 million allocated to repurchasing common stock under a 10b5-1 plan over the next 12 months and $100 million allocated to repurchasing common stock at management's discretion during open trading windows.
- Announced that the Wellcome Trust Sanger Institute purchased 20 HiSeq 2000s.
- Announced that the Broad Institute purchased 51 HiSeq 2000s to replace their current installed base of Genome AnalyzerIIx systems.
- Commenced shipment of the HumanOmni2.5-Quad DNA Analysis BeadChip, a four sample microarray with approximately 2.5 million markers per sample, including significant content derived from the 1000 Genomes Project.
- Received FDA 510(k) clearance for the BeadXpress(R) Multiplex Analysis System and VeraCode(R) Genotyping Test for Factor V Leiden and Factor II (Prothrombin).
- Reduced the price of the Company's Individual Genome Sequencing service from $48,000 to $19,500 per genome. Additionally, the Company announced a price of $14,500 per genome for groups of 5 or more participants using the same physician and a price of $9,500 per genome for individuals whose physicians have determined that whole-genome sequencing could provide potential direct clinical value in light of their serious medical conditions.
- Named Gerald Moeller, Ph.D. to the Board of Directors.
- Appointed Nicholas Naclerio to Senior Vice President of Corporate and Venture Development, Elizabeth Brady to Vice President of Global Supply Chain, Emily Winn-Deen to Vice President of Diagnostics Development, Melina Cimler to Vice President of Quality and Regulatory Affairs, and appointed Tristan Orpin to Chief Commercial Officer.
Financial Outlook and Guidance:
The non-GAAP financial guidance discussed below excludes the incremental interest expense associated with the company's convertible debt instruments that may be settled in cash, the double dilution associated with the accounting treatment of the company's outstanding convertible debt and the corresponding call option overlay, the amortization expense related to intangible assets, contingent compensation expense and the accrual of in-process research and development, the gain on acquisition, and acquisition related expense (see table which reconciles these non-GAAP financial measures to the related GAAP measures).
The company expects:
- Revenue growth for the full year 2010 of approximately 28% from 2009 revenue of $666 million.
- Gross margins for the second half of 2010 to be in the mid 60s (%) and in the mid to high 60s (%) for the full year 2010.
- Non-GAAP earnings per share between $0.93 and $1.00 including the dilution associated with the acquisition of Helixis.
- Full year pro forma tax rate of approximately 35%.
- Stock compensation expense of approximately $72 million or $0.34 per pro forma fully diluted share.
- Full year weighted average diluted shares outstanding for the measurement of pro forma results of approximately 136 million.
Quarterly Conference Call Information
The conference call will begin at 2:00pm Pacific Time (5:00pm Eastern Time) on Tuesday, July 27, 2010. Interested parties may listen to the call by dialing 866.510.0710 (passcode: 84755429), or if outside North America, by dialing +1.617.597.5378 (passcode: 84755429). Individuals may access the live teleconference under the "Corporate/Investor Information" tab of Illumina's web site at http://www.illumina.com.
A replay of the conference call will be available from 5:00pm Pacific Time (8:00pm Eastern Time) on July 27, 2010 through August 3, 2010 by dialing 888.286.8010, or if outside North America, by dialing +1.617.801.6888 (passcode: 99073585).
Statement Regarding Use of Non-GAAP Financial Measures
The company reports non-GAAP results for diluted net income per share, net income, gross margins, operating margins, and free cash flow in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.
The company's financial results under GAAP include substantial non-cash and other charges related to stock compensation expense, incremental interest expense and a gain on debt extinguishment associated with the company's convertible debt instruments that may be settled in cash, a gain on the acquisition of an investee accounted for using the cost method of accounting prior to acquisition, amortization expense related to intangible assets, in-process research and development and contingent compensation expense related to the acquisition of Avantome, Inc., acquisition expense, and expense related to acquired research and development. Per share amounts also include the double dilution associated with the accounting treatment of the company's convertible debt outstanding and the corresponding call option overlay. Management believes that presentation of operating results that excludes these charges provides useful supplemental information to investors and facilitates the analysis of the company's core operating results and comparison of operating results across reporting periods. Management also believes that this supplemental non-GAAP information is therefore useful to investors in analyzing and assessing the company's past and future operating performance.
The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP results are presented in the tables of this release.
Use of Forward Looking Statements
This release contains projections, information about our financial outlook, earnings guidance, and other forward-looking statements that involve risks and uncertainties. These forward-looking statements are based on our expectations as of the date of this release and may differ materially from actual future events or results. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are (i) our ability to develop and commercialize further our BeadArray(TM), VeraCode(R), and Solexa(R) technologies and to deploy new sequencing, gene expression, and genotyping products and applications for our technology platforms, (ii) our ability to manufacture robust instrumentation and reagents technology, and (iii) reductions in the funding levels to our primary customers, including as a result of the timing and amount of funding provided by the American Recovery and Reinvestment Act of 2009, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current financial quarter.
About Illumina
Illumina (http://www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
| Illumina, Inc. | ||||||
| Condensed Consolidated Balance Sheets | ||||||
| (In thousands) | ||||||
| July 4, 2010 | January 3, 2010 | |||||
| ASSETS | (unaudited) | |||||
| Current assets: | ||||||
| Cash and cash equivalents | $ | 237,187 | $ | 144,633 | ||
| Short-term investments | 548,193 | 548,894 | ||||
| Accounts receivable, net | 147,939 | 157,751 | ||||
| Inventory, net | 119,445 | 92,776 | ||||
| Deferred tax assets, current portion | 19,158 | 20,021 | ||||
| Prepaid expenses and other current assets | 16,345 | 17,515 | ||||
| Total current assets | 1,088,267 | 981,590 | ||||
| Property and equipment, net | 122,398 | 117,188 | ||||
| Goodwill | 271,819 | 213,452 | ||||
| Intangible assets, net | 70,298 | 43,788 | ||||
| Deferred tax assets, long-term portion | 45,579 | 47,371 | ||||
| Other assets | 43,524 | 26,548 | ||||
| Total assets | $ | 1,641,885 | $ | 1,429,937 | ||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
| Current liabilities: | ||||||
| Accounts payable | $ | 57,574 | $ | 52,781 | ||
| Accrued liabilities | 123,577 | 98,253 | ||||
| Long-term debt, current portion | 300,705 | 290,202 | ||||
| Total current liabilities | 481,856 | 441,236 | ||||
| Other long-term liabilities | 33,775 | 24,656 | ||||
| Conversion option subject to cash settlement | 89,294 | 99,797 | ||||
| Stockholders' equity | 1,036,960 | 864,248 | ||||
| Total liabilities and stockholders' equity | $ | 1,641,885 | $ | 1,429,937 | ||
| Illumina, Inc. | ||||||||||||||||
| Condensed Consolidated Statements of Operations | ||||||||||||||||
| (In thousands, except per share amounts) | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| July 4, 2010 | June 28, 2009 | July 4, 2010 | June 28, 2009 | |||||||||||||
| Revenue: | ||||||||||||||||
| Product revenue | $ | 198,538 | $ | 153,204 | $ | 372,217 | $ | 309,403 | ||||||||
| Service and other revenue | 13,465 | 8,439 | 31,917 | 17,997 | ||||||||||||
| Total revenue | 212,003 | 161,643 | 404,134 | 327,400 | ||||||||||||
| Cost of Revenue: | ||||||||||||||||
| Cost of product revenue (a) | 59,627 | 45,812 | 112,566 | 96,519 | ||||||||||||
| Cost of service and other revenue (a) | 4,690 | 3,003 | 10,084 | 6,318 | ||||||||||||
| Amortization of intangible assets | 1,595 | 1,670 | 3,215 | 3,340 | ||||||||||||
| Total cost of revenue | 65,912 | 50,485 | 125,865 | 106,177 | ||||||||||||
| Gross profit | 146,091 | 111,158 | 278,269 | 221,223 | ||||||||||||
| Operating Expenses: | ||||||||||||||||
| Research and development (a) | 43,667 | 33,117 | 87,343 | 65,843 | ||||||||||||
| Selling, general and administrative (a) | 53,671 | 41,939 | 103,950 | 84,770 | ||||||||||||
| Acquired in-process research and development | 1,325 | - | 1,325 | - | ||||||||||||
| Total operating expense | 98,663 | 75,056 | 192,618 | 150,613 | ||||||||||||
| Income from operations | 47,428 | 36,102 | 85,651 | 70,610 | ||||||||||||
| Other income (expense), net: | ||||||||||||||||
| Interest income | 1,751 | 2,576 | 3,955 | 5,492 | ||||||||||||
| Interest expense | (6,134 | ) | (5,713 | ) | (12,089 | ) | (11,397 | ) | ||||||||
| Other income (expense), net | 3,481 | 2,058 | 2,369 | (331 | ) | |||||||||||
| Total other expense, net | (902 | ) | (1,079 | ) | (5,765 | ) | (6,236 | ) | ||||||||
| Income before income taxes | 46,526 | 35,023 | 79,886 | 64,374 | ||||||||||||
| Provision for income taxes | 16,730 | 10,335 | 28,882 | 20,875 | ||||||||||||
| Net income | $ | 29,796 | $ | 24,688 | $ | 51,004 | $ | 43,499 | ||||||||
| Net income per basic share | $ | 0.24 | $ | 0.20 | $ | 0.42 | $ | 0.35 | ||||||||
| Net income per diluted share | $ | 0.21 | $ | 0.18 | $ | 0.37 | $ | 0.32 | ||||||||
| Shares used in calculating basic net income per share | 123,095 | 123,511 | 121,882 | 122,633 | ||||||||||||
| Shares used in calculating diluted net income per share | 140,951 | 139,465 | 138,682 | 136,220 | ||||||||||||
| (a) Includes total stock-based compensation expense for employee stock options and stock purchases: | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| July 4, 2010 | June 28, 2009 | July 4, 2010 | June 28, 2009 | |||||||||||||
| Cost of product revenue | $ | 1,301 | $ | 1,198 | $ | 2,510 | $ | 2,472 | ||||||||
| Cost of service and other revenue | 146 | 143 | 257 | 284 | ||||||||||||
| Research and development | 6,032 | 4,979 | 11,930 | 9,601 | ||||||||||||
| Selling, general and administrative | 9,366 | 8,581 | 19,147 | 17,404 | ||||||||||||
| Stock-based compensation expense before taxes | $ | 16,845 | $ | 14,901 | $ | 33,844 | $ | 29,761 | ||||||||
| Illumina, Inc. | ||||||||||||||||
| Condensed Consolidated Statements of Cash Flows | ||||||||||||||||
| (In thousands) | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| July 4, 2010 | June 28, 2009 | July 4, 2010 | June 28, 2009 | |||||||||||||
| Net cash provided by operating activities | $ | 74,796 | $ | 39,369 | $ | 130,323 | $ | 90,117 | ||||||||
| Net cash used in investing activities | (95,735 | ) | (73,310 | ) | (119,666 | ) | (113,128 | ) | ||||||||
| Net cash provided by financing activities | 43,216 | 39,133 | 77,522 | 46,946 | ||||||||||||
| Effect of exchange rate changes on cash and cash equivalents | 1,685 | (4,241 | ) | 4,375 | 1,138 | |||||||||||
| Net increase in cash and cash equivalents | 23,962 | 951 | 92,554 | 25,073 | ||||||||||||
| Cash and cash equivalents, beginning of period | 213,225 | 351,146 | 144,633 | 327,024 | ||||||||||||
| Cash and cash equivalents, end of period | $ | 237,187 | $ | 352,097 | $ | 237,187 | $ | 352,097 | ||||||||
| Calculation of free cash flow (a): | ||||||||||||||||
| Net cash provided by operating activities | $ | 74,796 | $ | 39,369 | $ | 130,323 | $ | 90,117 | ||||||||
| Purchases of property and equipment | (13,142 | ) | (14,022 | ) | (24,322 | ) | (26,591 | ) | ||||||||
| Free cash flow | $ | 61,654 | $ | 25,347 | $ | 106,001 | $ | 63,526 | ||||||||
| (a) Free cash flow, which is a non-GAAP financial measure, is calculated as net cash provided by operating activities reduced by purchases of property and equipment. Free cash flow is useful to management as it is one of the metrics used to evaluate our performance and to compare us with other companies in our industry. However, our calculation of free cash flow may not be comparable to similar measures used by other companies. | ||||||||||||||||
| Illumina, Inc. | ||||||||||||||||
| Results of Operations - Non-GAAP | ||||||||||||||||
| (In thousands, except per share amounts) | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| AN ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP NET INCOME PER SHARE: | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| July 4, 2010 | June 28, 2009 | July 4, 2010 | June 28, 2009 | |||||||||||||
| GAAP net income per share - diluted | $ | 0.21 | $ | 0.18 | $ | 0.37 | $ | 0.32 | ||||||||
| Pro forma impact of weighted average shares | 0.02 | 0.01 | 0.01 | 0.01 | ||||||||||||
| Adjustments to net income: | ||||||||||||||||
| Pro forma impact of non-cash interest expense (a) | 0.02 | 0.02 | 0.05 | 0.05 | ||||||||||||
| Other pro forma adjustments | 0.01 | 0.01 | 0.03 | 0.04 | ||||||||||||
| Non-GAAP net income per share - diluted (b) | $ | 0.26 | $ | 0.22 | $ | 0.46 | $ | 0.42 | ||||||||
| Shares used in calculating non-GAAP diluted net income per share | 132,547 | 132,329 | 130,757 | 129,084 | ||||||||||||
| AN ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP NET INCOME: | ||||||||||||||||
| GAAP net income | $ | 29,796 | $ | 24,688 | $ | 51,004 | $ | 43,499 | ||||||||
| Non-cash interest expense (a) | 5,156 | 4,758 | 10,210 | 9,476 | ||||||||||||
| Gain on acquisition (c) | (2,914 | ) | - | (2,914 | ) | - | ||||||||||
| Amortization of intangible assets | 1,595 | 1,670 | 3,215 | 3,340 | ||||||||||||
| Acquired in-process research and development | 1,325 | - | 1,325 | - | ||||||||||||
| Compensation expense (d) | 919 | 919 | 1,838 | 1,838 | ||||||||||||
| Acquisition expense | 536 | - | 536 | - | ||||||||||||
| Acquired research and development | - | - | - | 2,000 | ||||||||||||
| Gain on extinguishment of debt | - | - | - | (767 | ) | |||||||||||
| Pro forma impact on tax expense: | ||||||||||||||||
| Non-cash interest expense (a) | (2,032 | ) | (1,783 | ) | (4,012 | ) | (3,603 | ) | ||||||||
| Other pro forma adjustments | (345 | ) | (1,086 | ) | (608 | ) | (1,194 | ) | ||||||||
| Incremental non-GAAP tax expense (e) | (2,377 | ) | (2,869 | ) | (4,620 | ) | (4,797 | ) | ||||||||
| Non-GAAP net income (b) | $ | 34,036 | $ | 29,166 | $ | 60,594 | $ | 54,589 | ||||||||
| (a) Non-cash interest expense is calculated in accordance with the authoritative accounting guidance for convertible debt instruments that may be settled in cash. | ||||||||||||||||
| (b) Non-GAAP net income per share and net income exclude the effect of the pro forma adjustments as detailed above. Non-GAAP diluted net income per share and net income are key drivers of our core operating performance and major factors in management's bonus compensation each year. Management has excluded the effects of these items in these measures to assist investors in analyzing and assessing our past and future core operating performance. | ||||||||||||||||
| (c) Gain on acquisition represents the difference between the carrying value of a cost method investment in Helixis, Inc. prior to acquisition and the fair value of that investment at the time of acquisition. | ||||||||||||||||
| (d) Compensation expense represents contingent consideration for post-combination services associated with a prior acquisition. This expense is included within research and development on our statements of operations. | ||||||||||||||||
| (e) Incremental non-GAAP tax expense reflects the increase to GAAP tax expense related to the non-GAAP adjustments listed above. | ||||||||||||||||
| Illumina, Inc. | ||||||||||||||||||||||||||||
| Results of Operations - Non-GAAP (continued) | ||||||||||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||||||||||
| AN ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP RESULTS OF OPERATIONS AS A PERCENT OF REVENUE: | ||||||||||||||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||||
| July 4, 2010 | June 28, 2009 | July 4, 2010 | June 28, 2009 | |||||||||||||||||||||||||
| GAAP gross profit | $ | 146,091 | 68.9 | % | $ | 111,158 | 68.8 | % | $ | 278,269 | 68.9 | % | $ | 221,223 | 67.6 | % | ||||||||||||
| Stock-based compensation expense | 1,447 | 0.7 | % | 1,341 | 0.8 | % | 2,767 | 0.7 | % | 2,756 | 0.8 | % | ||||||||||||||||
| Amortization of intangible assets | 1,595 | 0.8 | % | 1,670 | 1.0 | % | 3,215 | 0.8 | % | 3,340 | 1.0 | % | ||||||||||||||||
| Non-GAAP gross profit | $ | 149,133 | 70.3 | % | $ | 114,169 | 70.6 | % | $ | 284,251 | 70.3 | % | $ | 227,319 | 69.4 | % | ||||||||||||
| Research and development expense | $ | 43,667 | 20.6 | % | $ | 33,117 | 20.5 | % | $ | 87,343 | 21.6 | % | $ | 65,843 | 20.1 | % | ||||||||||||
| Stock-based compensation expense | (6,032 | ) | (2.8 | %) | (4,979 | ) | (3.1 | %) | (11,930 | ) | (3.0 | %) | (9,601 | ) | (2.9 | %) | ||||||||||||
| Compensation Expense (a) | (919 | ) | (0.4 | %) | (919 | ) | (0.6 | %) | (1,838 | ) | (0.5 | %) | (1,838 | ) | (0.6 | %) | ||||||||||||
| Acquired research and development | - | - | - | - | - | - | (2,000 | ) | (0.6 | %) | ||||||||||||||||||
| Non-GAAP research and development expense | $ | 36,716 | 17.3 | % | $ | 27,219 | 16.8 | % | $ | 73,575 | 18.2 | % | $ | 52,404 | 16.0 | % | ||||||||||||
| Selling, general and administrative expense | $ | 53,671 | 25.3 | % | $ | 41,939 | 25.9 | % | $ | 103,950 | 25.7 | % | $ | 84,770 | 25.9 | % | ||||||||||||
| Stock-based compensation expense | (9,366 | ) | (4.4 | %) | (8,581 | ) | (5.3 | %) | (19,147 | ) | (4.7 | %) | (17,404 | ) | (5.3 | %) | ||||||||||||
| Acquisition expense | (536 | ) | (0.3 | %) | - | - | (536 | ) | (0.1 | %) | - | - | ||||||||||||||||
| Non-GAAP selling, general and administrative expense | $ | 43,769 | 20.6 | % | $ | 33,358 | 20.6 | % | $ | 84,267 | 20.9 | % | $ | 67,366 | 20.6 | % | ||||||||||||
| GAAP operating profit | $ | 47,428 | 22.4 | % | $ | 36,102 | 22.3 | % | $ | 85,651 | 21.2 | % | $ | 70,610 | 21.6 | % | ||||||||||||
| Stock-based compensation expense | 16,845 | 7.9 | % | 14,901 | 9.2 | % | 33,844 | 8.4 | % | 29,761 | 9.1 | % | ||||||||||||||||
| Amortization of intangible assets | 1,595 | 0.8 | % | 1,670 | 1.0 | % | 3,215 | 0.8 | % | 3,340 | 1.0 | % | ||||||||||||||||
| Acquired in-process research and development | 1,325 | 0.6 | % | - | - | 1,325 | 0.3 | % | - | - | ||||||||||||||||||
| Compensation expense (a) | 919 | 0.4 | % | 919 | 0.6 | % | 1,838 | 0.5 | % | 1,838 | 0.6 | % | ||||||||||||||||
| Acquisition expense | 536 | 0.3 | % | - | - | 536 | 0.1 | % | - | |||||||||||||||||||
| Acquired research and development | - | - | - | - | - | - | 2,000 | 0.6 | % | |||||||||||||||||||
| Non-GAAP operating profit (b) | $ | 68,648 | 32.4 | % | $ | 53,592 | 33.2 | % | $ | 126,409 | 31.3 | % | $ | 107,549 | 32.8 | % | ||||||||||||
| (a) Compensation expense represents contingent consideration for post-combination services associated with a prior acquisition. This expense is included within research and development on our statements of operations. | ||||||||||||||||||||||||||||
| (b) Non-GAAP operating profit excludes the effect of the pro forma adjustments as detailed above. Management has excluded the effects of these items in these measures to assist investors in analyzing and assessing our past and future core operating performance. Non-GAAP gross profit, included within the non-GAAP operating profit, is a key measure of the effectiveness and efficiency of our manufacturing processes, product mix and the average selling prices of our products and services. | ||||||||||||||||||||||||||||
| Illumina, Inc. | ||
| Reconciliation of Non-GAAP Financial Guidance | ||
| The financial guidance provided below is an estimate based on information available as ofJuly 27, 2010. The company's future performance and financial results are subject to risks and uncertainties, and actual results could differ materially from the guidance set forth below. Some of the factors that could affect the company's financial results are stated above in this press release. More information on potential factors that could affect the company's financial results is included from time to time in the company's public reports filed with the SEC, including the company's Form 10-K for the fiscal year ended January 3, 2010, the company's Form 10-Q for the fiscal quarter ended April 4, 2010 and the company's Form 10-Q for the fiscal quarter ended July 4, 2010 to be filed with the SEC. The company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates. | ||
| Diluted net income per share | ||
| Fiscal Year 2010 | ||
| Non-GAAP | $0.93 - $1.00 | |
| Non-cash interest expense (a) | ($0.09) | |
| Pro forma impact of weighted average shares (b) | ($0.05) | |
| Amortization of intangible assets | ($0.04) | |
| Other non-GAAP adjustments (c) | ($0.03) | |
| GAAP | $0.72 - $0.79 | |
| (a) Non-cash interest expense is calculated in accordance with the authoritative accounting guidance for convertible debt instruments that may be settled in cash. | ||
| (b) Pro forma impact of weighted average shares represents the estimated impact of double dilution associated with the accounting treatment of the company's outstanding convertible debt and the corresponding call option overlay. | ||
| (c) Other non-GAAP adjustments reflect the estimated impact on diluted net income per share for fiscal year 2010 from contingent compensation expense and the accrual of in-process research and development, the gain on acquisition, and acquisition related expense. | ||
SOURCE: Illumina, Inc.
Illumina, Inc.
Investors: Peter J. Fromen
Senior Director
Investor Relations
858-202-4507
pfromen@illumina.com
or
Media: Wilson Grabill
Senior Manager
Public Relations
858-882-6822
wgrabill@illumina.com
